Literature DB >> 16904946

Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease.

Vincent Wai-Sun Wong1, Alex Yui Hui, Steven Woon-Choy Tsang, Joyce Lai-Yee Chan, Ada Mei-Ling Tse, Kui-Fat Chan, Wing-Yee So, Angela Yuen-Shan Cheng, Wing-Fung Ng, Grace Lai-Hung Wong, Joseph Jao-Yiu Sung, Henry Lik-Yuen Chan.   

Abstract

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome are reaching epidemic levels worldwide, but data in Asia remain scarce. This cross-sectional study examined the metabolic and adipokine profiles of Chinese patients with biopsy-proven NAFLD and factors associated with severe disease.
METHODS: Eighty ethnic Chinese with NAFLD and 41 healthy controls were recruited. Metabolic parameters and fasting adiponectin, tumor necrosis factor-alpha (TNF-alpha), leptin, and resistin levels were measured on the day of liver biopsy. Histology was scored according to Brunt's criteria. Metabolic syndrome was assessed by using both the International Diabetes Federation and Adult Treatment Panel III criteria.
RESULTS: Twenty-eight patients had simple steatosis, and 52 patients had nonalcoholic steatohepatitis (NASH), defined as necroinflammatory grade >/=2 and/or fibrosis by Brunt's criteria. The ethnic-specific International Diabetes Federation criteria identified more cases of metabolic syndrome among NAFLD patients than the Adult Treatment Panel III criteria (70% vs 56%, P < .0001). On multivariate analysis, low adiponectin level, increased leptin level, and diabetes mellitus were associated with NAFLD. High TNF-alpha level and high body mass index were independent factors associated with NASH. TNF-alpha level had positive correlation with necroinflammatory grade (R = .35, P = .002) and fibrosis stage (R = .31, P = .005).
CONCLUSIONS: Hypoadiponectinemia and elevated TNF-alpha levels are associated with the development of NAFLD and NASH, respectively, independent of other metabolic factors. Ethnic-specific definition of metabolic syndrome is more useful in the assessment of NAFLD patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16904946     DOI: 10.1016/j.cgh.2006.06.011

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  50 in total

1.  High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial.

Authors:  Stefan B Puchner; Michael T Lu; Thomas Mayrhofer; Ting Liu; Amit Pursnani; Brian B Ghoshhajra; Quynh A Truong; Stephen D Wiviott; Jerome L Fleg; Udo Hoffmann; Maros Ferencik
Journal:  Radiology       Date:  2014-11-04       Impact factor: 11.105

Review 2.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 3.  Fatty liver in childhood.

Authors:  Yesim Ozturk; Ozlem Bekem Soylu
Journal:  World J Hepatol       Date:  2014-01-27

4.  Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells.

Authors:  Wei Cui; Stephen L Chen; Ke-Qin Hu
Journal:  Am J Transl Res       Date:  2010-01-01       Impact factor: 4.060

Review 5.  Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Sanja Stojsavljević; Marija Gomerčić Palčić; Lucija Virović Jukić; Lea Smirčić Duvnjak; Marko Duvnjak
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

6.  Abdominal obesity, glucose intolerance and decreased high-density lipoprotein cholesterol as components of the metabolic syndrome are associated with the development of colorectal cancer.

Authors:  Yoon Jin Choi; Dong Ho Lee; Kyung-Do Han; Cheol Min Shin; Nayoung Kim
Journal:  Eur J Epidemiol       Date:  2018-09-08       Impact factor: 8.082

Review 7.  Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic.

Authors:  Kareem Hassan; Varun Bhalla; Mohammed Ezz El Regal; H Hesham A-Kader
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

8.  Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis.

Authors:  Noha F Hassan; Somaia A Nada; Azza Hassan; Mona R El-Ansary; Muhammad Y Al-Shorbagy; Rania M Abdelsalam
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

9.  Risk of Colorectal Neoplasia According to Fatty Liver Severity and Presence of Gall Bladder Polyps.

Authors:  Taeyoung Lee; Kyung Eun Yun; Yoosoo Chang; Seungho Ryu; Dong Il Park; Kyuyong Choi; Yoon Suk Jung
Journal:  Dig Dis Sci       Date:  2015-09-18       Impact factor: 3.199

Review 10.  NAFLD in Asia--as common and important as in the West.

Authors:  Geoffrey C Farrell; Vincent Wai-Sun Wong; Shiv Chitturi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-05       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.